Table 1.

Time to first OSA event for patients without OSA at baseline

	All ertugliflozin (N = 5126)		Placebo (N = 2557)		HR* (95% CI)
	No. (%)	Rate/1000 patient- years	No. (%)	Rate/1000 patient- years
OSA event	22 (0.43)	1.4	19 (0.74)	2.6	0.52 (0.28–0.96); P = 0.04

OSA events are based on adverse events that occurred between the date of the first dose of study medication until treatment end plus an additional 14 days

^*Ertugliflozin (pooled) vs. placebo, based on the stratified Cox proportional hazards model that includes categorical terms for treatment, sex, geographical region, baseline BMI, baseline HbA1c, and baseline eGFR, a continuous term for age, and a stratification factor for enrollment cohort

BMI body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, HR hazard ratio, OSA obstructive sleep apnea